(NewsDirect)
Therma Bright Inc CEO Rob Fia discussesthe imminent decision on permanent codes for Venowave, its compact,lightweight deep vein thrombosis (DVT) prevention device, withProactive's Stephen Gunnion.
Fia said the importance of securing these codes from the Centersfor Medicare and Medicaid Services (CMS) lies in easier reimbursementprocesses, streamlining billing, and facilitating distribution.
Venowave is a groundbreaking compressiondevice that actively moves blood from the calf to the heart,FDA-approved for preventing blood clots and addressing issues likedeep vein thrombosis, chronic venous insufficiency, and varicoseveins. Unlike pneumatic devices in the market, Venowave employswaveform technology, setting it apart.
Fia highlighted the potential market size, estimated at over abillion dollars, and the significant advantage of holding the firstpermanent code for a compression device.
The CEO also elaborated on the expanding US distributionnetwork, including partnerships with a Medicare Advantage healthcareprovider and Texas-based doctors' groups. These partnerships offerdirect engagement with payers, facilitating billing and reimbursement.
Moreover, Therma Bright is alsofinalizing agreements with a distributor in Connecticut.
Theanticipated outcome of securing permanent codes for Venowave couldrevolutionize the industry, simplifying processes and enhancing marketreach, Fia said.
Contact Details
ProactiveInvestors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.